Literature DB >> 35110687

Large-scale structural network change correlates with clinical response to rTMS in depression.

Daniel M Blumberger1,2, Jonathan Downar3,4,5, Sean M Nestor1,6, Arsalan Mir-Moghtadaei7,8, Fidel Vila-Rodriguez9, Peter Giacobbe6,10,11, Zafiris J Daskalakis12.   

Abstract

Response to repetitive transcranial magnetic stimulation (rTMS) among individuals with major depressive disorder (MDD) varies widely. The neural mechanisms underlying rTMS are thought to involve changes in large-scale networks. Whether structural network integrity and plasticity are associated with response to rTMS therapy is unclear. Structural MRIs were acquired from a series of 70 adult healthy controls and 268 persons with MDD who participated in two arms of a large randomized, non-inferiority trial, THREE-D, comparing intermittent theta-burst stimulation to high-frequency rTMS of the left dorsolateral prefrontal cortex (DLPFC). Patients were grouped according to percentage improvement on the 17-item Hamilton Depression Rating Score at treatment completion. For the entire sample and then for each treatment arm, multivariate analyses were used to characterize structural covariance networks (SCN) from cortical gray matter thickness, volume, and surface area maps from T1-weighted MRI. The association between SCNs and clinical improvement was assessed. For both study arms, cortical thickness and volume SCNs distinguished healthy controls from MDD (p = 0.005); however, post-hoc analyses did not reveal a significant association between pre-treatment SCN expression and clinical improvement. We also isolated an anticorrelated SCN between the left DLPFC rTMS target site and the subgenual anterior cingulate cortex across cortical measures (p = 0.0004). Post-treatment change in cortical thickness SCN architecture was associated with clinical improvement in treatment responders (p = 0.001), but not in non-responders. Structural network changes may underpin clinical response to rTMS, and SCNs are useful for understanding the pathophysiology of depression and neural mechanisms of plasticity and response to circuit-based treatments.
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Year:  2022        PMID: 35110687      PMCID: PMC8938539          DOI: 10.1038/s41386-021-01256-3

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   8.294


  56 in total

Review 1.  The Neural Crossroads of Psychiatric Illness: An Emerging Target for Brain Stimulation.

Authors:  Jonathan Downar; Daniel M Blumberger; Zafiris J Daskalakis
Journal:  Trends Cogn Sci       Date:  2015-12-03       Impact factor: 20.229

2.  Noninvasive Brain Stimulation for Depression - The Devil Is in the Dosing.

Authors:  Sarah H Lisanby
Journal:  N Engl J Med       Date:  2017-06-29       Impact factor: 91.245

3.  Subgenual Functional Connectivity Predicts Antidepressant Treatment Response to Transcranial Magnetic Stimulation: Independent Validation and Evaluation of Personalization.

Authors:  Robin F H Cash; Andrew Zalesky; Richard H Thomson; Ye Tian; Luca Cocchi; Paul B Fitzgerald
Journal:  Biol Psychiatry       Date:  2019-01-19       Impact factor: 13.382

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments.

Authors:  Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 5.  Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis.

Authors:  Bradley N Gaynes; Stacey W Lloyd; Linda Lux; Gerald Gartlehner; Richard A Hansen; Shannon Brode; Daniel E Jonas; Tammeka Swinson Evans; Meera Viswanathan; Kathleen N Lohr
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

6.  A multivariate neuroimaging biomarker of individual outcome to transcranial magnetic stimulation in depression.

Authors:  Robin F H Cash; Luca Cocchi; Rodney Anderson; Anton Rogachov; Aaron Kucyi; Alexander J Barnett; Andrew Zalesky; Paul B Fitzgerald
Journal:  Hum Brain Mapp       Date:  2019-07-22       Impact factor: 5.038

7.  Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate.

Authors:  Michael D Fox; Randy L Buckner; Matthew P White; Michael D Greicius; Alvaro Pascual-Leone
Journal:  Biol Psychiatry       Date:  2012-06-01       Impact factor: 13.382

8.  Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.

Authors:  John P O'Reardon; H Brent Solvason; Philip G Janicak; Shirlene Sampson; Keith E Isenberg; Ziad Nahas; William M McDonald; David Avery; Paul B Fitzgerald; Colleen Loo; Mark A Demitrack; Mark S George; Harold A Sackeim
Journal:  Biol Psychiatry       Date:  2007-06-14       Impact factor: 13.382

9.  Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression.

Authors:  M S George; E M Wassermann; W A Williams; A Callahan; T A Ketter; P Basser; M Hallett; R M Post
Journal:  Neuroreport       Date:  1995-10-02       Impact factor: 1.837

10.  Orbitofrontal Cortex: A 'Non-rewarding' New Treatment Target in Depression?

Authors:  Jonathan Downar
Journal:  Curr Biol       Date:  2019-01-21       Impact factor: 10.834

View more
  1 in total

1.  Baseline Clinical and Neuroimaging Biomarkers of Treatment Response to High-Frequency rTMS Over the Left DLPFC for Resistant Depression.

Authors:  Ghina Harika-Germaneau; Issa Wassouf; Tom Le Tutour; Remy Guillevin; Damien Doolub; Reza Rostami; Alexia Delbreil; Nicolas Langbour; Nematollah Jaafari
Journal:  Front Psychiatry       Date:  2022-05-20       Impact factor: 5.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.